Management of hepatitis C viral infection in HIV-positive patients taking antiretroviral treatment;Prise en charge de l'infection virale C chez les patients coinfectés par le VIH recevant un traitement antirétroviral

Presse Medicale

Volumn 30, Issue 14, 2001, Pages 677-682

  Pol, S ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; RIBAVIRIN;

ANTIVIRAL ACTIVITY; CONTAMINATION; DISEASE SEVERITY; DRUG EFFICACY; EARLY DIAGNOSIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREVALENCE; REVIEW; TOXIC HEPATITIS; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 17644430878     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections
2. Progression and clinical outcome of infection due to human immunodeficiency virus
3. Hepatitis C virus infection in patients infected with the human immunodeficiency virus
4. Coinfecton of hepatitis C virus with immunodeficiency virus and progression to AIDS
5. Does hepatitis C virus coinfection accelerate clinical and immunological evolution of HIV-infected patients?
6. The association between hepatitis C virus and immunodeficiency virus disease progression in a cohort of hemophilic men
7. High hepatitis viremia and impaired antibody response in patients coinfected with HIV
8. Hepatitis C virus (HCV) viremia in Human Immunodeficiency Virus-seronegative and seropositive patients with indeterminate HCV recombinant immunoblot assay
9. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users
10. Maternal-infant transmission of hepatitis C virus and HIV infections: A possible interaction
11. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and infants transmission study
12. Heterosexual cotransmission of hepatitis C virus and human immunodeficiency virus
13. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation
14. Rapidly progressive Non-A, Non-B hepatitis in patients with human immunodeficiency virus infection
15. The natural history of parenterally-acquired chronic hepatitis C
16. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
17. Liver fibrosis progression in HIV-HCV coinfected patients
18. Mortalité par cirrhose virale C chez les patients infectés par le VIH dans les services de médecine interne et de pathologie infectieuse en 1997
19. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
20. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
21. Treatment of chronic hepatitis C with recombinant interferon alpha
22. Hepatitis C virus type 1b (II) infection in France and Italy
23. Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study
24. Treatment of special populations
25. Efficacy and safety of alpha-Interferon treatment for chronic hepatitis C in HIV-infected patients
26. Randomized trial of interferon 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
27. Efficacy and safety of combination therapy with interferon-alpha 2b and ribavirin for chronic hepatitis C in HIV-infected patients
28. Ribavirin antagonizes the effect of azidothymidine on HIV replication
29. Antiretroviral drugs for AIDS
30. Anti-HIV tritherapy does not modify HCV replication in coinfected subjects
31. Effect of interferon and ribavirin on HIV viral load
32. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
33. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus
34. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor
35. Hepatitis C virus associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
36. Rapidly evolving hepatitis C virus-associated cirrhosis in HIV coinfected patient in relation to antiretroviral tritherapy
37. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection
38. Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1 infected patients
39. Anti-protease inhibitor decreases the liver fibrosis progression rate in HIV-HCV coinfected patients
40. Fulminant hepatic failure associated with 2′, 3′-dideoxyinosine (ddl)
41. Severe hepatic cytolysis in patients treated by highly active antiretroviral therapy (HAART) with protease inhibitor or with two nucleoside reverse transcriptase inhibitors (NRTIs)
42. Severe hepatitis in three AIDS patients treated by indinavir
43. Elevated liver enzymes following initiation of antiretroviral therapy
44. Impact of HIV coinfection on the long-term follow-up of HCV-related cirrhosis